BioNxt Solutions (TSE:BNXT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioNxt Solutions has expanded its patent portfolio by filing new international patents for sublingual drug delivery technologies, targeting autoimmune neurodegenerative diseases like Multiple Sclerosis and Myasthenia Gravis. The company aims to initiate clinical trials for its lead product, BNT23001, in 2025, with plans to develop strategic partnerships to accelerate commercialization.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.